Welcome to LookChem.com Sign In|Join Free
  • or
Benzaldehyde, 5-chloro-2-[(4-methoxyphenyl)methoxy]- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

632625-64-0

Post Buying Request

632625-64-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

632625-64-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 632625-64-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,2,6,2 and 5 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 632625-64:
(8*6)+(7*3)+(6*2)+(5*6)+(4*2)+(3*5)+(2*6)+(1*4)=150
150 % 10 = 0
So 632625-64-0 is a valid CAS Registry Number.

632625-64-0Relevant academic research and scientific papers

PIPERIDINE DERIVATIVE

-

Paragraph 0502; 0604, (2019/02/19)

The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis, multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.

AMINONITRILES AS KYNURENINE PATHWAY INHIBITORS

-

Page/Page column 81, (2014/09/29)

The present application provides novel kynurenine pathway inhibitors and pharmaceutically acceptable salts and prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in regulating the kynurenine pathway and the activity of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase by administering a therapeutically effective amount of one or more of the compounds of formula (I) to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the kynurenine pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by immunosuppression, abnormal cellular proliferation and/or inflammation. In one embodiment, the disease is cancer. In another embodiment, the disease is a viral infection. In a further embodiment, the disease is depression.

Concise approach to 1,4-dioxygenated xanthones via novel application of the Moore rearrangement

Nichols, Alexander L.,Zhang, Patricia,Martin, Stephen F.

supporting information; experimental part, p. 7591 - 7597 (2012/09/21)

The rapid synthesis of 1,4-dioxygenated xanthones and related natural products employing the Moore rearrangement as a key transformation has been developed. The approach features an acetylide stitching step to unite a substituted squaric acid with a protected hydroxy benzaldehyde derivative to provide a key intermediate that undergoes facile Moore rearrangement to deliver a hydroxymethyl aryl quinone. Subsequent oxidation, hydroxy group deprotection and cyclization then affords highly functionalized xanthones. The utility of the approach was demonstrated by its application to a concise and efficient synthesis of the naturally-occurring xanthone 1. The structure of a natural product that had been named dulcisxanthone C was also corrected to that of the xanthone 1.

General and expedient synthesis of 1,4-dioxygenated xanthones

Nichols, Alexander L.,Zhang, Patricia,Martin, Stephen F.

supporting information; experimental part, p. 4696 - 4699 (2011/10/09)

A facile entry to 1,4-dioxygenated xanthones having a variety of substitution patterns and substituents was developed that features a novel application of the Moore cyclization using substrates that were readily assembled in a highly convergent fashion by an acetylide stitching process. The practical utility of the methodology was demonstrated by an efficient synthesis of a naturally occurring xanthone and correction of the structure of dulcisxanthone C.

PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES

-

Page 44, (2010/02/05)

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 632625-64-0